With a more favourable environment, HUADONG MEDICINE CO improves to Slightly Positive
HUADONG MEDICINE CO (CN), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 2 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date December 17, 2021, the closing price was CNY 35.56 and its potential was estimated at CNY 46.09.Huadong Medicine is engaged in the manufacture of medicine; sales of sterilization antiseptic products, medical equipment, glass instruments, daily-use chemical products, household electrical appliances, agricultural by-products, general merchandise, native products, articles of artistic industry, knitted textiles and healthcare products; and warehousing activities. Through its subsidiaries, Co. is engaged in the pharmaceutical industry and industrial investments; sales of Chinese medicine, biological products; and development of biological medicine technology.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.